111 related articles for article (PubMed ID: 11602420)
1. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders.
Mazza P; Palazzo G; Amurri B; Pricolo G; Prudenzano A; Stani L
Haematologica; 2001 Oct; 86(10):1104-5. PubMed ID: 11602420
[No Abstract] [Full Text] [Related]
2. Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab.
Svoboda J; Kotloff R; Tsai DE
Transpl Int; 2006 Apr; 19(4):259-69. PubMed ID: 16573540
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for lymphoproliferative disease prior to haematopoietic stem cell transplantation for X-linked severe combined immunodeficiency.
Trahair TN; Wainstein B; Manton N; Bourne AJ; Ziegler JB; Rice M; Russell SJ
Pediatr Blood Cancer; 2008 Feb; 50(2):366-9. PubMed ID: 16732583
[TBL] [Abstract][Full Text] [Related]
4. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab.
Skoda-Smith S; Douglas VK; Mehta P; Graham-Pole J; Wingard JR
Bone Marrow Transplant; 2001 Feb; 27(3):329-32. PubMed ID: 11277182
[TBL] [Abstract][Full Text] [Related]
5. Delay in B-lymphocyte recovery and function following rituximab for EBV-associated lymphoproliferative disease early post-allogeneic hematopoietic SCT.
Masjosthusmann K; Ehlert K; Eing BR; Roth J; Koehler G; Juergens H; Fruehwald M; Groll AH
Bone Marrow Transplant; 2009 May; 43(9):679-84. PubMed ID: 19029962
[TBL] [Abstract][Full Text] [Related]
6. Primary nonresponse to anti-cd20 therapy in gastrointestinal posttransplant lymphoproliferative disorder.
Gökçe S; Süoğlu OD; Sökücü S; Gün F; Emiroğlu H; Celik A; Doğan O; Cevikbaş U
J Pediatr Gastroenterol Nutr; 2006 Mar; 42(3):316-20. PubMed ID: 16540802
[No Abstract] [Full Text] [Related]
7. Post-transplant lymphoproliferative disorder treated with rituximab: case report.
Meng HT; Li Y; Liu JH; Xu GX; Teng XD
Chin Med J (Engl); 2007 May; 120(9):841-3. PubMed ID: 17531130
[No Abstract] [Full Text] [Related]
8. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab.
Kordelas L; Trenschel R; Koldehoff M; Elmaagacli A; Beelen DW
Onkologie; 2008 Dec; 31(12):691-3. PubMed ID: 19060508
[TBL] [Abstract][Full Text] [Related]
10. PTLD treatment: reducing the chemotherapy burden through addition of rituximab.
Dharnidharka VR; Gupta S
Pediatr Transplant; 2010 Feb; 14(1):10-1. PubMed ID: 20078838
[No Abstract] [Full Text] [Related]
11. Rituximab purging and maintenance combined with auto-SCT: long-term molecular remissions and prolonged hypogammaglobulinemia in relapsed follicular lymphoma.
Hicks LK; Woods A; Buckstein R; Mangel J; Pennell N; Zhang L; Imrie K; Spaner D; Cheung MC; Boudreau A; Reis M; Crump M; Berinstein NL
Bone Marrow Transplant; 2009 May; 43(9):701-8. PubMed ID: 19029963
[TBL] [Abstract][Full Text] [Related]
12. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
[TBL] [Abstract][Full Text] [Related]
13. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease.
González-Barca E; Domingo-Domenech E; Capote FJ; Gómez-Codina J; Salar A; Bailen A; Ribera JM; López A; Briones J; Muñoz A; Encuentra M; de Sevilla AF; ; ;
Haematologica; 2007 Nov; 92(11):1489-94. PubMed ID: 18024397
[TBL] [Abstract][Full Text] [Related]
14. Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies.
Putkonen M; Rauhala A; Pelliniemi TT; Remes K
Ann Hematol; 2009 Jul; 88(7):673-80. PubMed ID: 19139894
[TBL] [Abstract][Full Text] [Related]
15. Rituximab for pure red cell aplasia after ABO-mismatched allogeneic peripheral blood progenitor cell transplantation.
Sorà F; De Matteis S; Piccirillo N; Chiusolo P; Laurenti L; Putzulu R; Leone G; Sica S
Transfusion; 2005 Apr; 45(4):643-5. PubMed ID: 15819690
[No Abstract] [Full Text] [Related]
16. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders.
Gordan LN; Grow WB; Pusateri A; Douglas V; Mendenhall NP; Lynch JW
J Clin Oncol; 2005 Feb; 23(6):1096-102. PubMed ID: 15657402
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant lymphoproliferative disorders after lung transplantation: first-line treatment with rituximab may induce complete remission.
Knoop C; Kentos A; Remmelink M; Garbar C; Goldman S; Feremans W; Estenne M
Clin Transplant; 2006; 20(2):179-87. PubMed ID: 16640524
[TBL] [Abstract][Full Text] [Related]
18. Successful prolonged rituximab treatment for post-transplant lymphoproliferative disorder following living donor liver transplantation in a child.
Hayashida M; Ogita K; Matsuura T; Takahashi Y; Nishimoto Y; Ohga S; Hara T; Soejima Y; Taketomi A; Maehara Y; Kohashi K; Tsuneyoshi M; Taguchi T
Pediatr Transplant; 2007 Sep; 11(6):671-5. PubMed ID: 17663692
[TBL] [Abstract][Full Text] [Related]
19. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy.
Kelaïdi C; Tulliez M; Lecoq-Lafon C; Pham XV; Kahan A; Dreyfus F; Bouscary D
Leukemia; 2002 Oct; 16(10):2173-4. PubMed ID: 12357380
[No Abstract] [Full Text] [Related]
20. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders.
Trapè G; Fianchi L; Lai M; Laurenti L; Piscitelli R; Leone G; Pagano L
Haematologica; 2003 Feb; 88(2):223-5. PubMed ID: 12604415
[No Abstract] [Full Text] [Related]
[Next] [New Search]
